Best Growth-Hormone Secretagogue Peptides Compared

At a glance: Comparing growth hormone secretagogues

Growth hormone secretagogues (GHS) represent a diverse class of synthetic signaling peptides studied for their capacity to stimulate endogenous growth hormone (GH) synthesis and secretion from the anterior pituitary gland. Rather than introducing exogenous GH, secretagogues operate via distinct physiological pathways: growth hormone-releasing hormone (GHRH) receptor agonists and ghrelin/growth hormone secretagogue receptor (GHS-R1a) agonists.

In preclinical settings, researchers differentiate these molecules based on receptor affinity, biological half-life, plasma protein binding, and selectivity. The top primary compounds under active investigation include Tesamorelin, CJC-1295 (with and without DAC), Ipamorelin, GHRP-2, GHRP-6, and Sermorelin. Each compound exhibits a distinct pharmacodynamic profile that dictates its utility in cellular signaling, metabolic rate, and somatotrophic axis research.

PX1 Research provides fully characterized, high-purity batches of these peptides, accompanied by complete lot-traceable analytical documentation. Researchers can review our complete catalog of research peptides or consult our peptide research database for underlying biochemical literature.

Selection criteria for secretagogue peptides in laboratory research

When designing protocol trials involving growth hormone secretagogues, laboratory investigators evaluate compounds using standardized bio-analytical criteria. Ranking these agents by cellular efficacy rather than non-scientific criteria ensures reproducible data across comparative assays.

Purity verification: High-performance liquid chromatography (HPLC) must confirm a minimum purity threshold of 99% to eliminate truncated peptide sequences that could interfere with receptor binding studies.

Pathway selectivity: The ability of a compound to trigger GH release without altering baseline cortisol, prolactin, or aldosterone levels is critical for controlled metabolic signaling experiments.

Biochemical stability: Structural modifications, such as N-terminal alterations or affinity complexes, dictate peptide degradation rates in cultured media or animal models.

Endotoxin levels: Bacterial endotoxin testing via Limulus Amebocyte Lysate (LAL) assay must confirm levels below standard cell-culture interference thresholds (<0.5 EU/mg).

Lot traceability: Complete batch documentation linking raw synthesis data directly to final vial analysis guarantees experimental continuity between studies.

Tesamorelin: Stabilized N-terminal GHRH analog

Tesamorelin is a synthetic 44-amino acid peptide representing an N-terminally modified analog of endogenous growth hormone-releasing hormone (GHRH). By incorporating a trans-3-hexenoic acid group at the N-terminus, Tesamorelin displays enhanced resistance to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), resulting in a significantly extended biological half-life compared to native GHRH(1-44).

Preclinical data indicate that Tesamorelin binds directly to GHRH receptors on pituitary somatotrophs, activating the adenylate cyclase signal transduction pathway. This cascade raises intracellular cyclic adenosine monophosphate (cAMP), prompting the transcription and pulsatile release of endogenous GH without destabilizing baseline glucose homeostasis in animal models.

Investigational studies utilize Tesamorelin to examine visceral adiposity reduction, ectopic fat deposition, and neuroprotective signaling pathways. PX1 Research supplies high-purity 10 mg Tesamorelin vials for in vitro assays. Researchers seeking further technical parameters can examine our detailed Tesamorelin research overview.

CJC-1295 No DAC (Mod GRF 1-29): Short-acting GHRH agonist

CJC-1295 No DAC, often referenced in biochemical literature as Modified GRF 1-29, is a 29-amino acid peptide derived from the active core sequence of GHRH. It contains four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) specifically engineered to resist enzymatic degradation while retaining full receptor activation potency.

In vitro signaling assays confirm that Mod GRF 1-29 stimulates GHRH receptors, generating sharp, physiological GH pulses that closely mimic natural somatotrophic rhythms. Because it lacks the Drug Affinity Complex (DAC), its half-life remains relatively brief (roughly 30 minutes), making it the standard choice for researchers seeking precise temporal control over GH pulsatility.

Laboratories investigating acute GH release kinetics routinely combine CJC-1295 No DAC with selective GHRPs to measure synergistic pituitary receptor response. PX1 Research manufactures verified 5 mg CJC-1295 No DAC vials. Complete biochemical specifications are detailed in our CJC-1295 No DAC reference guide.

CJC-1295 With DAC: Extended receptor activation complex

CJC-1295 With DAC incorporates a reactive Maleimidopropionic acid moiety at the C-terminus of the tetrasubstituted GHRH(1-29) chain. This Drug Affinity Complex (DAC) allows the peptide to covalently bind to circulating serum albumin post-administration in preclinical animal models, protecting the structure from renal clearance and enzymatic degradation.

This modification extends the active biological half-life of the peptide to several days, maintaining sustained elevation of basal growth hormone and insulin-like growth factor 1 (IGF-1) concentrations. Consequently, CJC-1295 With DAC is utilized in long-term metabolic studies where steady-state somatotroph stimulation is required rather than discrete physiological pulsing.

PX1 Research maintains rigorous purity protocols for all complex modified peptides, offering 5 mg CJC-1295 With DAC vials with verified identity. Learn more about affinity-bound peptide dynamics in our CJC-1295 DAC research section.

Ipamorelin: Highly selective ghrelin receptor agonist

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) classified as a growth hormone secretagogue receptor (GHS-R1a) agonist. It stands out among ghrelin mimetics for its exceptional receptor selectivity, demonstrating a complete absence of stimulation at receptors governing cortisol, ACTH, and prolactin secretion in animal models.

In cell culture and animal trials, Ipamorelin selectively triggers GH release by binding to central GHS-R1a sites. This mechanism operates synergistically when co-administered with GHRH analogs, as the two receptor pathways activate distinct intracellular messenger cascades (phospholipase C and cAMP, respectively) within pituitary somatotrophs.

Due to its minimal off-target activity, Ipamorelin is a primary tool for studying bone mineral density, nitrogen retention, and clean somatotrophic axis modulation. PX1 Research supplies batch-tested 10 mg Ipamorelin vials. Access technical documentation via our Ipamorelin research guide.

GHRP-2 (Pralmorelin): Potent synthetic GHS-R agonist

GHRP-2 (Pralmorelin) is a hexapeptide growth hormone secretagogue that acts as a potent agonist at the GHS-R1a receptor. It exhibits high binding affinity, promoting robust GH release in laboratory models that exceeds the amplitude of first-generation secretagogues.

Preclinical evaluation shows that while GHRP-2 is highly effective at raising serum GH levels, it induces a minor, dose-dependent rise in plasma cortisol and prolactin concentrations. Additionally, it displays modest ghrelin-like effects on appetite signaling centers in rodent CNS assays.

Researchers utilize GHRP-2 in comparative signaling studies to evaluate high-amplitude somatotrophic response curves against second-generation selective peptides. PX1 Research offers 10 mg GHRP-2 vials with full analytical COAs. Technical profile details are available in our GHRP-2 technical library.

GHRP-6: Classical ghrelin mimetic and appetite regulator

GHRP-6 is a hexapeptide belonging to the first generation of synthetic growth hormone secretagogues. It stimulates GH secretion via central GHS-R1a activation while simultaneously stimulating hypothalamic ghrelin circuits that modulate food intake and gastric motility in animal models.

In vitro experiments show that GHRP-6 activates protein kinase C (PKC) pathways, releasing intracellular calcium ions within somatotroph cells. Because it strongly induces orexigenic pathways alongside somatotrophic signaling, GHRP-6 is heavily utilized in energy balance, cachexia, and metabolic flux research.

PX1 Research provides analytical-grade 10 mg GHRP-6 vials tested for mass consistency and peptide content. Review the complete chemical property sheet in our GHRP-6 research library.

Sermorelin: Truncated N-terminal GHRH sequence

Sermorelin is a 29-amino acid peptide representing the shortest functional N-terminal fragment of native human GHRH (GHRH 1-29). It contains the fully active catalytic site required to bind and activate GHRH receptors on anterior pituitary cells.

Because it lacks structural modifications, Sermorelin exhibits a rapid clearance profile, making it a reliable reference standard for establishing baseline GHRH receptor responsiveness in comparative secretagogue research. Studies utilize Sermorelin to measure endogenous pituitary secretory reserve without risking long-term receptor down-regulation.

PX1 Research stocks fully characterized 5 mg Sermorelin vials for quantitative analytical applications. Access additional specifications through our Sermorelin technical resources.

How to vet a peptide supplier: Red flags in GHS procurement

Selecting a supplier for laboratory-grade growth hormone secretagogues requires verifying stringent quality assurance measures. Substandard or unverified peptides introduce experimental noise, batch variance, and cellular toxicity risks that compromise published data.

Red Flag 1: Lack of lot-specific COAs. A supplier providing static or template Certificates of Analysis without distinct lot numbers, HPLC chromatographs, and MS spectra fails basic traceability standards.

Red Flag 2: Absence of endotoxin quantification. Peptides intended for cell culture or animal research must be screened via LAL assay. High endotoxin levels trigger inflammatory responses that skew experimental endpoints.

Red Flag 3: Unverified overseas drop-shipping. Vendors operating without domestic US physical facilities often lack temperature-controlled storage, exposing freeze-dried peptides to heat degradation during transit.

Red Flag 4: Direct human dosing or therapeutic guidance. Compliant chemical supply organizations operate strictly within laboratory research boundaries. Vendors offering medical protocols violate regulatory standards.

To ensure verifiable data, procure materials only from suppliers that provide clear analytical documentation, solid-phase peptide synthesis (SPPS) verification, and domestic cold-chain distribution options. Bulk buyers can also explore our wholesale peptide program for high-volume assay requirements.

Ordering Growth Hormone Secretagogues from PX1 Research

When you order growth hormone secretagogue peptides from PX1 Research, your shipment contains lyophylized, vacuum-sealed glass vials engineered for long-term stability. Every single vial is assigned a specific lot number matching its analytical Certificate of Analysis, accessible directly through our online validation portal.

Available vial capacities range from 5 mg to 10 mg depending on the specific sequence, allowing laboratory teams to order precise quantities needed for their trial protocols. All orders placed before 3:00 PM EST Monday through Friday ship same-day from our dual distribution facilities in California and Arizona, utilizing priority tracked shipping to guarantee thermal integrity upon receipt.

PX1 Research maintains a dedicated scientific support desk to assist procurement managers with batch selection, documentation requests, and logistics tracking. Explore our complete line of growth hormone secretagogues and place your order directly through our secure platform.